In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

Cervical cancer rates are on the rise among younger women, owing in part to a lack of screening and prevention.

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

IN a powerful response to the World Health Organisation’s call for the global elimination of cervical cancer by 2030, ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or ...

The outcomes of this trial help confirm that cisplatin chemotherapy given adjuvantly with radiotherapy is not a superior alternative ,” said Sang Young Ryu, MD.

Over 70% of cancer deaths occur in low- and middle-income countries where rural populations face the highest risks due to ...

By Robert Andre Emmanuel robert.emmanuel@antiguaobserver.com Antigua and Barbuda took a groundbreaking step in cervical ...

Beyond prevention, the UAE’s strategy includes providing advanced treatment to those ... to the global strategy to eliminate cervical cancer. The HPV vaccine is administered intramuscularly.

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.